Medivir AB presented positive new data from its ongoing phase Ib / IIa study of fostroxacitabine bralpamide + Lenvima® in advanced hepatocellular carcinoma at the ESMO GI Cancers Congress in Munich, Germany.
- New results from Medivir’s Phase 1b / 2a open label trial of fostrox + Lenvima® show great promise treating second-line hepatocellular carcinoma (HCC) patients, an extremely hard to treat population
- Fostrox + Lenvima® achieved a 24% overall response rate (ORR) and estimated median time to progression (TTP) of 10.8 months1 (4.1 – NE) – with one patient still on treatment after 22 months
- Results come despite very poor prognosis for most second-line HCC patients today, with just 5 – 10% responding to current standard of care treatment, and a typical TTP of only 3 - 4 months
- Medivir’s fostrox (fostroxacitabine bralpamide) is an orally-administered, liver-targeted inhibitor of DNA replication. The mechanism is different to existing first-line HCC treatments, delivering its cell-killing compound selectively to tumor cells while minimizing harm to healthy cells
STOCKHOLM, June 27, 2024 /PRNewswire/ -- Medivir AB (NASDAQ: MVIR) (STOCKHOLM: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, today presented positive new data from its ongoing phase Ib / IIa study of fostroxacitabine bralpamide (fostrox) + Lenvima® in advanced hepatocellular carcinoma (HCC) at the ESMO GI (European Society of Medical Oncology, Gastrointestinal Cancers) Cancers Congress in Munich, Germany.
Today’s ESMO GI update, poster number 176P, is being presented by Dr Hong Jae Chon on Thursday June 27, shows:
- An overall response rate (ORR) of 24%, with a disease control rate (DCR) of 81%, while the median TTP is now 10.8 months, with 25% of patients still on treatment
- One patient remains on treatment after 22 months, benefiting from a sustained partial response
- Biopsies confirm selective DNA damage to tumor cells, while there is no impact on normal liver function as measured by ALT/ AST levels and stable ALBI score over time
The lack of impact on normal liver function supports the previously reported encouraging safety and tolerability profile, where only 5% of patients had to discontinue due to adverse events and the need for dose modification was lower than expected.
Jens Lindberg, CEO at Medivir, said: “With new data, including clear evidence of tumor selectivity, the clinical benefit of adding fostrox to Lenvima has greatly improved. We are particularly encouraged by the duration of benefit, with patients staying on treatment much longer than anticipated. Second-line hepatocellular carcinoma remains an indication with substantial need for improved outcomes for patients, with no approved treatment options after current standard of care. The data presented at ESMO GI makes us even more convinced of fostrox’s future potential in the treatment of HCC. We are now initiating study feasibility and finalizing the study protocol and synopsis which will lead to the opening of IND in the US, which is expected in H2 2024.”
Dr Hong Jae Chon, Professor at CHA Bundang Hospital in Korea, and investigator in the fostrox + Lenvima® study, commented: “Advanced hepatocellular cancer is a challenging disease to treat, especially in second-line after patients have stopped responding to an immunotherapy (IO) combination. There is a need for new treatments that do not worsen liver function and that have different mechanisms of action compared with first line. These data for fostrox + Lenvima show highly encouraging clinical benefits for patients. They indicate that when adding fostrox to Lenvima, efficacy is better than expected from Lenvima alone. I look forward to further explore the efficacy of fostrox plus Lenvima in a randomized, controlled trial.”
The data are from Medivir’s ongoing phase 1b/2a open-label, multi-center, dose-escalation and dose-expansion study, evaluating the safety and efficacy of fostrox in combination with Lenvima in patients for whom current first- or second-line treatment has proven ineffective or is not tolerable.
HCC is the most common type of liver cancer, accounting for more than 80% of cases worldwide.2 There are approximately 660,000 patients diagnosed with primary liver cancer per year globally and current five-year survival is less than 20 percent3.
The poster will also be available on Medivir’s website after it has been presented at ESMO GI.
For additional information, please contact:
Magnus Christensen, CFO, Medivir AB
Telephone: +46 8 5468 3100
E-mail: magnus.christensen@medivir.com
Optimum Strategic Communications
Nick Bastin, Stephen Adams, Eleanor Cooper
Telephone: +44 20 3922 0891
E-mail: medivir@optimumcomms.com
Cord Communications
Lars Wahlstrom, Adam Ewing
Telephone: +46 734 340 771
About fostrox
Fostrox is a liver-targeted inhibitor of DNA replication that delivers the cell-killing compound selectively to the tumor while minimizing the harmful effect on normal cells. This is achieved by coupling an active chemotherapy (troxacitabine) with a prodrug tail. This design enables fostrox to be administered orally and travel directly to the liver where the active substance is released locally in the liver. With this unique mechanism, fostrox has the potential to become the first liver-targeted, orally administered drug that can help patients with various types of liver cancer. A phase 1b monotherapy study with fostrox has been completed and a phase 1b/2a combination study in HCC is ongoing where it has shown encouraging anti-cancer efficacy with a good safety and tolerability profile.
About primary liver cancer
Primary liver cancer is the third leading cause of cancer-related deaths worldwide. Hepatocellular carcinoma (HCC) is the most common cancer that arises in the liver and it is the fastest growing cancer in the USA. Although existing therapies for advanced HCC can extend the lives of patients, treatment benefits are insufficient and death rates remain high. There are approximately 660,000 patients diagnosed with primary liver cancer per year globally and current five-year survival is less than 20 percent2,3. HCC is a heterogeneous disease with diverse etiologies, and lacks defining mutations observed in many other cancers. This has contributed to the lack of success of molecularly targeted agents in HCC. The limited overall benefit, taken together with the poor overall prognosis for patients with intermediate and advanced HCC, results in a large unmet medical need.
About Medivir
Medivir develops innovative drugs with a focus on cancer where the unmet medical needs are high. The drug candidates are directed toward indication areas where available therapies are limited or missing and there are great opportunities to offer significant improvements to patients. Medivir is focusing on the development of fostroxacitabine bralpamide (fostrox), a smart, targeted chemotherapy designed to selectively treat liver cancer cells and to minimize side effects. Collaborations and partnerships are important parts of Medivir’s business model, and the drug development is conducted either by Medivir or in partnership. Medivir’s share (ticker: MVIR) is listed on Nasdaq Stockholm’s Small Cap list. www.medivir.com.
1) Data cut-off 30 May, 2024
2) Rumgay et al.,European Journal of Cancer 2022 vol.161, 108-118.
3) Yang, J.D., Hainaut, P., Gores, G.J. et al. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol 16, 589–604 (2019).
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
| Medivir ESMO GI PR_27 June ENG |
View original content:https://www.prnewswire.com/news-releases/fostrox--lenvima-holds-promise-of-greatly-improved-outcomes-for-advanced-liver-cancer-patients-reveals-new-data-from-medivir-at-esmo-gi-302184220.html
SOURCE Medivir
Company Codes: Bloomberg:MVIR@SS, ISIN:SE0020181014, RICS:MVIR.ST, Stockholm:MVIR
